234 related articles for article (PubMed ID: 20460919)
1. Animal models of non-alcoholic steatohepatitis: of mice and man.
Schattenberg JM; Galle PR
Dig Dis; 2010; 28(1):247-54. PubMed ID: 20460919
[TBL] [Abstract][Full Text] [Related]
2. Animal models of NASH: getting both pathology and metabolic context right.
Larter CZ; Yeh MM
J Gastroenterol Hepatol; 2008 Nov; 23(11):1635-48. PubMed ID: 18752564
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic steatohepatitis in children.
Nanda K
Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
[TBL] [Abstract][Full Text] [Related]
4. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?
Ariz U; Mato JM; Lu SC; Martínez Chantar ML
Methods Mol Biol; 2010; 593():109-36. PubMed ID: 19957147
[TBL] [Abstract][Full Text] [Related]
7. Interstrain differences in susceptibility to non-alcoholic steatohepatitis.
Yamazaki Y; Kakizaki S; Takizawa D; Ichikawa T; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2008 Feb; 23(2):276-82. PubMed ID: 17868334
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Miele L; Forgione A; Gasbarrini G; Grieco A
Transl Res; 2007 Mar; 149(3):114-25. PubMed ID: 17320797
[TBL] [Abstract][Full Text] [Related]
9. Commonly used animal models of non-alcoholic steatohepatitis.
Fan JG; Qiao L
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):233-40. PubMed ID: 19502161
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice.
Wouters K; van Bilsen M; van Gorp PJ; Bieghs V; Lütjohann D; Kerksiek A; Staels B; Hofker MH; Shiri-Sverdlov R
FEBS Lett; 2010 Mar; 584(5):1001-5. PubMed ID: 20114046
[TBL] [Abstract][Full Text] [Related]
11. Metabolic disturbances in non-alcoholic fatty liver disease.
Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
[TBL] [Abstract][Full Text] [Related]
12. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
13. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
[TBL] [Abstract][Full Text] [Related]
14. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.
Koppe SW; Sahai A; Malladi P; Whitington PF; Green RM
J Hepatol; 2004 Oct; 41(4):592-8. PubMed ID: 15464239
[TBL] [Abstract][Full Text] [Related]
15. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
16. [Nonalcoholic steatohepatitis--a "new" hepatic disease].
Grønbaek H; Eivindson MV; Hamilton-Dutoit S; Vilstrup H
Ugeskr Laeger; 2003 Mar; 165(11):1115-8. PubMed ID: 12677985
[TBL] [Abstract][Full Text] [Related]
17. Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis.
Rangnekar AS; Lammert F; Igolnikov A; Green RM
Liver Int; 2006 Oct; 26(8):1000-5. PubMed ID: 16953841
[TBL] [Abstract][Full Text] [Related]
18. Hepatic microcirculation in fatty liver disease.
Farrell GC; Teoh NC; McCuskey RS
Anat Rec (Hoboken); 2008 Jun; 291(6):684-92. PubMed ID: 18484615
[TBL] [Abstract][Full Text] [Related]
19. The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis.
Miele L; Forgione A; Hernandez AP; Gabrieli ML; Vero V; Di Rocco P; Greco AV; Gasbarrini G; Gasbarrini A; Grieco A
Eur Rev Med Pharmacol Sci; 2005; 9(5):273-7. PubMed ID: 16231589
[TBL] [Abstract][Full Text] [Related]
20. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
